Medacta Group SA (MOVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medacta Group SA (MOVE) has a cash flow conversion efficiency ratio of 0.172x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF72.95 Million ≈ $92.23 Million USD) by net assets (CHF424.61 Million ≈ $536.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Medacta Group SA to measure how much of total assets are equity-financed.
Medacta Group SA - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Medacta Group SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MOVE cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Medacta Group SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medacta Group SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Park National Corporation
NYSE MKT:PRK
|
0.043x |
|
Henan Mingtai Al.Industrial Co Ltd
SHG:601677
|
-0.013x |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
0.028x |
|
Companhia Energética de Minas Gerais - CEMIG
SA:CMIG3
|
0.038x |
|
WD-40 Company
NASDAQ:WDFC
|
0.038x |
|
Sichuan Hebang Biotechnology Co Ltd
SHG:603077
|
0.009x |
|
Softcat plc
F:SF5
|
0.107x |
|
Academy Sports Outdoors Inc
NASDAQ:ASO
|
0.069x |
Annual Cash Flow Conversion Efficiency for Medacta Group SA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Medacta Group SA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Medacta Group SA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF379.66 Million ≈ $480.00 Million |
CHF107.14 Million ≈ $135.46 Million |
0.282x | +23.97% |
| 2023-12-31 | CHF330.04 Million ≈ $417.26 Million |
CHF75.13 Million ≈ $94.98 Million |
0.228x | -14.95% |
| 2022-12-31 | CHF274.65 Million ≈ $347.24 Million |
CHF73.51 Million ≈ $92.94 Million |
0.268x | +12.08% |
| 2021-12-31 | CHF226.40 Million ≈ $286.23 Million |
CHF54.06 Million ≈ $68.35 Million |
0.239x | -34.00% |
| 2020-12-31 | CHF164.72 Million ≈ $208.25 Million |
CHF59.59 Million ≈ $75.34 Million |
0.362x | +4.57% |
| 2019-12-31 | CHF123.23 Million ≈ $155.80 Million |
CHF42.63 Million ≈ $53.90 Million |
0.346x | -53.60% |
| 2018-12-31 | CHF89.07 Million ≈ $112.61 Million |
CHF66.41 Million ≈ $83.96 Million |
0.746x | +46.94% |
| 2017-12-31 | CHF101.67 Million ≈ $128.54 Million |
CHF51.59 Million ≈ $65.22 Million |
0.507x | +32.33% |
| 2016-12-31 | CHF146.87 Million ≈ $185.69 Million |
CHF56.31 Million ≈ $71.19 Million |
0.383x | -- |
About Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.